Christopher Neff
Myriad Genetics
7 Papers
23 Citations
Christopher Neff is an academic researcher from Myriad Genetics. The author has contributed to research in topics: Homologous recombination & Germline. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.
Euan A. Stronach,James Paul,Kirsten Timms,Elisha Hughes,Krystal Brown,Christopher Neff,Michael C. Perry,Alexander Gutin,Mona El-Bahrawy,Jennifer H. Steel,Xinxue Liu,Liz-Anne Lewsley,Nadeem Siddiqui,Hani Gabra,Hani Gabra,Jerry S. Lanchbury,Robert S. Brown +16 more
TL;DR: HRD, tumor BRCA1/2 mutations, and absence of CCNE1 amplification are associated with improved survival of ovarian cancer patients treated with platinum monotherapy and HRD-positive patients may benefit from platinum dose intensification.
Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors.
Keith M. Wilcoxen,Marc A. Becker,Christopher Neff,Victor Abkevich,Joshua Jones,Xiaonan Hou,Yan Wang,Anne-Renee Hartman,Mariam M. AlHilli,Alexander Gutin,Shefali Agarwal,Kirsten Timms,Paul Haluska +12 more
TL;DR: An HRD test is being applied to patient samples to identify BRCA mutated tumors, provide a categorical determination of tumor HRD, and determine an enrichment strategy for patients with tumors that are sensitive to niraparib treatment.
18
Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer.
Melinda L. Telli,Kirsten Timms,Julia Reid,Christopher Neff,Victor Abkevich,Alexander Gutin,Zaina Sangale,Diana Illiev,Joshua Jones,Bryan T. Hennessy,Jerry S. Lanchbury,Gordon B. Mills,Anne-Renee Hartman,James M. Ford +13 more
TL;DR: The combined HRD score, an unweighted sum of LOH, telomeric allelic imbalance (TAI) and large-scale state transitions (LST) scores are found to be a more robust predictor of HR deficiency than the individual components.
8
Clinical significance of homologous recombination deficiency (HRD) score testing in endometrial cancer patients.
Jean M. Hansen,Kari L. Ring,Keith A. Baggerly,Sherry Y. Wu,Kirsten Timms,Christopher Neff,Elisha Hughes,Rebecca A. Previs,Russell Broaddus,Robert L. Coleman,Karen H. Lu,Anil K. Sood +11 more
TL;DR: HRD score is related to chemotherapy response in both triple negative breast and high-grade serous ovarian cancers and the role of HRD is unknown in endometrial cancer.
4
Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors.
Kirsten Timms,Anees B. Chagpar,Vikram B. Wali,Veerle Bossuyt,Julia Reid,Alexander Gutin,Christopher Neff,Erin Hofstatter,Jerry S. Lanchbury,Lajos Pusztai +9 more
TL;DR: This study assesses the consistency of the HRD score in multiple biopsies obtained from the same cancer to examine the impact of spatial heterogeneity and sampling on the results.
3